BTO Meeting ECPA – CAB Andriukaitis

16-11-2015

Participants: [redacted] *(ECPA), N. Chaze (CAB Andriukaitis),* [redacted] *(SANTE)*

- ECPA requested this meeting with a view to the meeting of the ECPA board next week.

Classification

- ECPA is not happy with the Commission policy to take decisions under chapter 3.6 of Annex II to Regulation 1107/2009 based on EFSA classification proposals. ECPA believes that ECHA is the only EU agency to be involved in questions around classification of chemicals according to Regulation 1272/2008.

- N. Chaze states that the Commission has full confidence in the scientific work done by EFSA. In addition, the policy referred to by ECPA reflects the particular role EFSA plays for the decision making under Regulation 1107/2009.

- N. Chaze agrees that differences in classification between EFSA and ECHA are not wishful. She reminds that, however, the pertinent founding legislation for EFSA and ECHA respectively foresee procedures for the case of scientific divergence with other international scientific bodies.

- N. Chaze informs ECPA that EFSA and ECHA work together towards a process to make sure that the processes of classification under Regulation 1272/2008 and approval according to Regulation 1107/2009 can run in parallel and are finished around the same time, wherever possible.

Delays in decision-making

- ECPA finds the extension of approval of 6 months for a number of substances under renewal too short.

- N. Chaze expresses her confidence in the process and the deadlines.

MRLs

- ECPA informs about a complaint to the European Ombudsman concerning the timing of approvals and MRL setting. ECPA believes that the Commission should take a decision on

MRLs immediately after an EFSA conclusion is available and not wait for the approval of the substance.

- N. Chaze replies that the reference values are only established after the finalization of the review and the vote on the approval of a substance in the Standing Committee. Before that date, no MRLs should be set. In order to avoid necessary delays, the Commission envisages presenting an MRL proposal as soon as possible after the approval of an active substance was supported by the Standing Committee.